Table 2.
Distribution of comorbidities in various age group of patients with COVID-19 positive.
| Variables | Age group in years (%) |
P value | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 0–9 | 10–19 | 20–29 | 30–39 | 40–49 | 50–59 | 60–69 | Above 70 | ||
| Total, N | 5 | 51 | 319 | 205 | 161 | 139 | 63 | 23 | .011 |
| Comorbidities | 0 (0%) | 3 (5.9%) | 21 (6.6%) | 29 (14.1%) | 50 (31.1%) | 58 (41.7%) | 36 (57.1%) | 11 (47.8%) | .05 |
| Hypertension | |||||||||
| Diabetes | 0 (0%) | 0 (0%) | 4 (1.3%) | 10 (4.9%) | 34 (21.1%) | 48 (34.5%) | 32 (50.8%) | 13 (56.5%) | .001 |
| Heart diseases | 0 (0%) | 0 (0%) | 7 (2.2%) | 6 (2.9%) | 25 (15.5%) | 37 (26.6%) | 23 (36.5%) | 11 (47.8%) | .024 |
| Gastrointestinal diseases | 0 (0%) | 3 (5.9%) | 17 (5.3%) | 5 (2.4%) | 8 (5%) | 9 (6.5%) | 4 (6.3%) | 3 (13%) | .041 |
| Kidney diseases | 0 (0%) | 2 (3.9%) | 2 (0.6%) | 4 (2%) | 6 (3.7%) | 8 (5.8%) | 10 (15.9%) | 8 (34.8%) | .033 |
| Liver diseases | 0 (0%) | 0 (0%) | 6 (1.9%) | 6 (2.9%) | 13 (8.1%) | 6 (4.3%) | 5 (7.9%) | 3 (13%) | .001 |
| Asthma | 0 (0%) | 1 (2%) | 6 (1.9%) | 8 (3.9%) | 3 (1.9%) | 2 (1.4%) | 1 (1.6%) | 0 (0%) | .496 |
| Cancer | 0 (0%) | 0 (0%) | 2 (0.6%) | 0 (0%) | 1 (0.6%) | 1 (0.7%) | 3 (4.8%) | 4 (17.4%) | .731 |
| Tuberculosis | 0 (0%) | 2 (3.9%) | 7 (2.2%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | .435 |
| Others | 0 (0%) | 2 (3.9%) | 14 (4.4%) | 6 (2.9%) | 7 (4.3%) | 6 (4.3%) | 3 (4.8%) | 5 (21.7%) | .142 |
| No comorbidity | 5 (100%) | 40 (78.4%) | 252 (79%) | 135 (65.9%) | 65 (40.4%) | 39 (28.1%) | 4 (6.3%) | 1 (4.3%) | .019 |
| ∗With Comorbidity | 0 (0%) | 11 (21.6%) | 67 (21%) | 70 (34.1%) | 96 (59.6%) | 100 (71.9%) | 59 (93.7%) | 22 (95.7%) | .004 |